You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.

Open menu


Galapagos reports early clinical results for SIK inhibitor

Galapagos has reported early results from three studies of its salt inducible kinase (SIK) 2/3 inhibitor GLPG3970, the first candidate from its portfolio of SIK inhibitor compounds.